Clinical Approach to Muscle Weakness
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of muscle weakness
Muscle weakness is one of the most common and diagnostically challenging complaints encountered in clinical practice, accounting for approximately 5% of all primary care visits and up to 10% of neurology consultations. The lifetime prevalence of significant muscle weakness is estimated at 10-15% of the general population. Weakness can range from mild functional impairment to life-threatening respiratory failure, making accurate localization and diagnosis essential. The diagnostic yield improves dramatically when clinicians systematically localize the lesion along the motor pathway before generating a differential diagnosis.
Definition
True weakness (paresis or plegia) refers to a reduction in the maximum force a muscle can generate, resulting from dysfunction anywhere along the motor pathway from the cerebral cortex to the muscle fiber itself. This must be distinguished from perceived weakness (asthenia or fatigue), where patients report feeling weak but demonstrate normal muscle strength on examination. True weakness implies pathology of the nervous system or muscle, while perceived weakness often reflects systemic illness, deconditioning, or psychiatric conditions.
Classification by Duration
| Category | Duration | Common Causes | Clinical Significance |
|---|---|---|---|
| Acute | Hours to days (less than 4 weeks) | Stroke, Guillain-Barré syndrome, acute transverse myelitis, myasthenic crisis, periodic paralysis, rhabdomyolysis | Often represents neurological emergency; requires urgent evaluation for reversible causes |
| Subacute | Weeks to months (4 weeks to 6 months) | Inflammatory myopathies, subacute combined degeneration, paraneoplastic syndromes, chronic inflammatory demyelinating polyneuropathy | Suggests inflammatory, infectious, or neoplastic etiology; often treatable if identified early |
| Chronic | Greater than 6 months | Muscular dystrophies, motor neuron disease, hereditary neuropathies, inclusion body myositis, chronic denervation | Often progressive and degenerative; focus on establishing diagnosis, prognosis, and supportive care |
Classification by Distribution Pattern
Proximal Weakness
Affected muscles: Shoulder girdle (deltoid, supraspinatus) and hip girdle (iliopsoas, glutei, quadriceps)
Functional impact: Difficulty rising from chairs, climbing stairs, reaching overhead, combing hair
Suggests: Myopathy (inflammatory, metabolic, toxic), neuromuscular junction disorders, some motor neuron diseases
Distal Weakness
Affected muscles: Intrinsic hand muscles, wrist extensors, ankle dorsiflexors, foot intrinsics
Functional impact: Difficulty with fine motor tasks, foot drop, tripping, hand grip weakness
Suggests: Peripheral neuropathy, distal myopathies, motor neuron disease (amyotrophic lateral sclerosis)
Symmetric Weakness
Pattern: Both sides of the body affected equally
Suggests: Myopathy, neuromuscular junction disorders, polyneuropathy, systemic causes
Asymmetric Weakness
Pattern: One side or specific muscle groups affected more than others
Suggests: Stroke, radiculopathy, mononeuropathy, motor neuron disease, focal central nervous system lesion
Classification by Motor Neuron Type
| Feature | Upper Motor Neuron Weakness | Lower Motor Neuron Weakness |
|---|---|---|
| Lesion Location | Motor cortex, internal capsule, brainstem, spinal cord (above anterior horn) | Anterior horn cell, nerve root, peripheral nerve, neuromuscular junction, muscle |
| Distribution | Pyramidal pattern: arm extensors and leg flexors weaker | Follows specific nerve root, peripheral nerve, or muscle pattern |
| Muscle Tone | Increased (spasticity) — velocity-dependent | Decreased (flaccidity or hypotonia) |
| Deep Tendon Reflexes | Hyperreflexia, clonus | Hyporeflexia or areflexia |
| Pathological Reflexes | Babinski sign positive (extensor plantar response) | Babinski sign negative (flexor plantar response) |
| Muscle Bulk | Preserved initially; late mild atrophy from disuse | Early and prominent atrophy |
| Fasciculations | Absent | Present (especially in anterior horn cell disease) |
Classification by Temporal Pattern
| Pattern | Description | Suggests |
|---|---|---|
| Sudden onset (seconds to minutes) | Weakness develops abruptly, often with maximal deficit at onset | Vascular event (stroke, spinal cord infarction), trauma |
| Rapid progressive (hours to days) | Weakness worsens over short period, may ascend | Guillain-Barré syndrome, acute transverse myelitis, myasthenic crisis |
| Fluctuating | Weakness varies throughout the day or with activity | Myasthenia gravis (worse with use, better with rest), periodic paralysis |
| Episodic | Discrete attacks of weakness with normal intervals | Periodic paralysis, transient ischemic attack, multiple sclerosis relapse |
| Progressive (months to years) | Gradual worsening without remission | Motor neuron disease, muscular dystrophy, chronic neuropathy, inclusion body myositis |
| Static or slowly progressive | Weakness present from birth or early life, minimal change | Congenital myopathies, cerebral palsy, hereditary conditions |
Key Concept: The Localization Principle
The foundation of evaluating muscle weakness is anatomical localization along the motor pathway. Before generating a differential diagnosis, clinicians must determine where the lesion is located:
- Central nervous system: Brain (cortex, internal capsule, brainstem) or spinal cord
- Anterior horn cell: Motor neuron cell bodies in the spinal cord
- Peripheral nerve: Nerve roots, plexus, or peripheral nerves
- Neuromuscular junction: The synapse between nerve and muscle
- Muscle: The muscle fiber itself (myopathy)
Each location produces a characteristic pattern of weakness, reflexes, sensory findings, and associated features that guide the diagnostic workup.
2. Pathophysiology and Mechanisms
Understanding the underlying mechanisms of muscle weakness
Understanding the motor pathway from cortex to muscle is essential for localizing weakness. Voluntary movement requires intact function at every level: the upper motor neuron (from cortex to spinal cord), the lower motor neuron (from spinal cord to muscle), the neuromuscular junction, and the muscle fiber itself. Dysfunction at any point produces weakness with characteristic clinical features that allow localization.
The Motor Pathway
| Component | Structure | Function |
|---|---|---|
| Upper Motor Neuron | Motor cortex (precentral gyrus) → corticospinal tract → descends through internal capsule, cerebral peduncle, pyramids → decussates at medullary pyramids → lateral corticospinal tract in spinal cord | Initiates voluntary movement; modulates and inhibits lower motor neuron activity; controls fine motor skills |
| Lower Motor Neuron | Anterior horn cells in spinal cord → ventral nerve roots → spinal nerves → peripheral nerves → terminal motor branches | Final common pathway for all motor activity; directly innervates muscle fibers; carries action potentials to neuromuscular junction |
| Neuromuscular Junction | Presynaptic terminal (acetylcholine vesicles) → synaptic cleft → postsynaptic membrane (nicotinic acetylcholine receptors) | Transmits signal from nerve to muscle; acetylcholine release triggers muscle fiber depolarization |
| Muscle Fiber | Sarcolemma → T-tubules → sarcoplasmic reticulum → myofibrils (actin and myosin filaments) | Excitation-contraction coupling; calcium-mediated cross-bridge cycling generates force |
Mechanisms of Weakness by Anatomical Location
Central Nervous System (Upper Motor Neuron)
Cerebral Cortex and Internal Capsule
Mechanism: Disruption of corticospinal neurons in motor cortex or their axons in the internal capsule
Causes: Stroke, tumor, abscess, demyelination
Pattern: Contralateral hemiparesis (face, arm, leg); arm often more affected than leg in cortical lesions
Brainstem
Mechanism: Damage to corticospinal tracts before or after decussation; involvement of cranial nerve nuclei
Causes: Brainstem stroke, multiple sclerosis, tumor
Pattern: Crossed findings — ipsilateral cranial nerve palsy with contralateral hemiparesis
Spinal Cord
Mechanism: Damage to lateral corticospinal tract; anterior horn cells may also be involved
Causes: Trauma, transverse myelitis, compression, infarction
Pattern: Weakness at and below lesion level; often bilateral; associated sensory level
Peripheral Nervous System (Lower Motor Neuron)
Anterior Horn Cell
Mechanism: Degeneration of motor neuron cell bodies; loss of entire motor units
Causes: Amyotrophic lateral sclerosis, spinal muscular atrophy, poliomyelitis
Clinical features: Fasciculations, early atrophy, no sensory loss (motor neurons only)
Nerve Root (Radiculopathy)
Mechanism: Compression or inflammation of nerve root at or near the spinal column
Causes: Disc herniation, spondylosis, tumor, infection
Pattern: Myotomal weakness with dermatomal sensory loss; single or multiple roots
Peripheral Nerve (Neuropathy)
Mechanism: Axonal degeneration, demyelination, or both; affects motor and often sensory fibers
Causes: Diabetes, Guillain-Barré syndrome, hereditary neuropathies, toxins
Pattern: Length-dependent (distal greater than proximal) or multifocal; sensory symptoms common
Neuromuscular Junction
| Condition | Mechanism | Key Features |
|---|---|---|
| Myasthenia Gravis | Autoantibodies against postsynaptic acetylcholine receptors (85%) or muscle-specific kinase (MuSK); reduced receptor density and impaired signal transmission | Fatigable weakness — worsens with repeated use, improves with rest; ptosis and diplopia common; no sensory loss; reflexes preserved |
| Lambert-Eaton Myasthenic Syndrome | Autoantibodies against presynaptic voltage-gated calcium channels; reduced acetylcholine release | Proximal weakness that improves with repeated effort (facilitation); autonomic symptoms; often paraneoplastic (small cell lung cancer) |
| Botulism | Botulinum toxin blocks presynaptic acetylcholine release by cleaving SNARE proteins | Descending paralysis; starts with cranial nerves (diplopia, dysphagia, dysarthria); dilated pupils; autonomic dysfunction |
Muscle (Myopathy)
| Type | Mechanism | Examples |
|---|---|---|
| Inflammatory Myopathies | Immune-mediated muscle fiber destruction; CD8+ T-cells (polymyositis, inclusion body myositis) or complement-mediated microangiopathy (dermatomyositis) | Polymyositis, dermatomyositis, inclusion body myositis, immune-mediated necrotizing myopathy |
| Muscular Dystrophies | Genetic mutations affecting structural proteins (dystrophin, sarcoglycans, others); progressive muscle fiber degeneration and fibrosis | Duchenne and Becker muscular dystrophy, limb-girdle muscular dystrophy, facioscapulohumeral dystrophy |
| Metabolic Myopathies | Defects in energy metabolism — glycogen storage, lipid metabolism, or mitochondrial function | McArdle disease (myophosphorylase deficiency), Pompe disease (acid maltase deficiency), mitochondrial myopathies |
| Toxic and Drug-Induced Myopathies | Direct muscle fiber toxicity, mitochondrial dysfunction, or immune-mediated damage | Statin myopathy, glucocorticoid myopathy, alcohol myopathy, colchicine myopathy |
| Endocrine Myopathies | Hormonal effects on muscle protein synthesis and degradation; electrolyte disturbances | Thyrotoxic myopathy, hypothyroid myopathy, Cushing syndrome myopathy, hypokalemic myopathy |
How Specific Conditions Cause Muscle Weakness
| Condition | Pathophysiological Mechanism | Treatment Implication |
|---|---|---|
| Guillain-Barré Syndrome | Post-infectious autoimmune attack on peripheral nerve myelin (AIDP) or axons (AMAN/AMSAN); demyelination causes conduction block and slowing | Immunotherapy (intravenous immunoglobulin or plasmapheresis) removes pathogenic antibodies; corticosteroids not effective |
| Amyotrophic Lateral Sclerosis | Progressive degeneration of both upper and lower motor neurons; exact mechanism unclear but involves protein aggregation, oxidative stress, and excitotoxicity | Riluzole (glutamate antagonist) provides modest survival benefit; supportive care is mainstay |
| Myasthenia Gravis | Antibody-mediated reduction in functional acetylcholine receptors at the neuromuscular junction | Acetylcholinesterase inhibitors increase available acetylcholine; immunosuppression reduces antibody production |
| Dermatomyositis | Complement-mediated destruction of intramuscular capillaries leading to muscle ischemia and perifascicular atrophy | Immunosuppression (corticosteroids, steroid-sparing agents) targets the autoimmune process |
| Hypokalemic Periodic Paralysis | Mutations in ion channels cause abnormal muscle membrane excitability; during attacks, potassium shifts intracellularly, hyperpolarizing muscle and preventing contraction | Potassium supplementation during attacks; acetazolamide for prophylaxis; avoid triggers (carbohydrate loads) |
| Critical Illness Myopathy | Combination of electrical silencing, catabolic state, immobilization, and medication effects (corticosteroids, neuromuscular blocking agents) causing myosin loss | Minimize corticosteroid and neuromuscular blocker use; early mobilization; nutritional support |
Often Overlooked Mechanism: The “Second Wind” Phenomenon
In McArdle disease (glycogen storage disease type V), patients experience muscle pain and weakness during the first few minutes of exercise, followed by improvement — the “second wind.” This occurs because the initial exercise relies on glycogenolysis (blocked in McArdle disease), but after several minutes, blood flow increases and alternative fuel sources (free fatty acids, blood glucose) become available. Recognizing this pattern can prompt testing for myophosphorylase deficiency even when resting creatine kinase is only mildly elevated.
Clinical Application: Mixed Upper and Lower Motor Neuron Signs
The presence of both upper and lower motor neuron signs in the same patient is a critical finding that should immediately raise concern for amyotrophic lateral sclerosis. Look for hyperreflexia and spasticity (upper motor neuron) combined with fasciculations, atrophy, and weakness (lower motor neuron) in multiple body regions. No other common condition produces this combination, making it virtually pathognomonic when present.
3. History Taking
A comprehensive approach to eliciting the muscle weakness history
Red Flags — Require Urgent Evaluation
- Respiratory muscle weakness — Dyspnea at rest, orthopnea, weak cough, unable to count to 20 in one breath (impending respiratory failure)
- Rapidly ascending weakness — Suggests Guillain-Barré syndrome; may progress to respiratory failure within hours
- Bulbar symptoms — Dysphagia, dysarthria, drooling (aspiration risk, possible myasthenic crisis or bulbar ALS)
- Acute onset with headache or altered consciousness — Suggests stroke or intracranial pathology
- Bladder or bowel dysfunction with weakness — Suggests spinal cord compression (cauda equina syndrome or myelopathy)
- Fever with acute weakness — Consider infectious causes (viral myositis, epidural abscess, poliomyelitis)
- Weakness after starting new medication — Drug-induced myopathy, serotonin syndrome, neuroleptic malignant syndrome
- Dark urine with muscle pain — Rhabdomyolysis with risk of acute kidney injury
Systematic History: The “WEAKNESS” Approach
Use the mnemonic “WEAKNESS” to ensure comprehensive history taking:
- W — Where is the weakness? Which muscles are affected? Proximal (shoulders, hips) or distal (hands, feet)? Symmetric or asymmetric? Face, eyes, or bulbar muscles involved?
- E — Evolution and onset: When did it start? Sudden (seconds), rapid (hours to days), or gradual (weeks to months)? Is it progressive, static, or fluctuating?
- A — Associated symptoms: Sensory changes (numbness, tingling)? Pain? Fatigue? Dysphagia? Diplopia? Ptosis? Respiratory difficulty? Bowel or bladder changes?
- K — Key triggers and modifiers: Worse with activity (myasthenia) or rest? Time of day variation? Effect of temperature? Triggered by exercise, fasting, or carbohydrates?
- N — Neurological review: Cognitive changes? Cranial nerve symptoms? Coordination problems? Gait disturbance? Previous similar episodes?
- E — Exposures and medications: Recent infections? New medications (statins, steroids, chemotherapy)? Toxins? Alcohol? Illicit drugs?
- S — Systemic and past history: Autoimmune diseases? Thyroid disorders? Diabetes? Malignancy? Family history of neuromuscular disease?
- S — Social and functional impact: Activities affected? Falling? Difficulty with stairs, rising from chairs, gripping objects? Occupation? Need for assistive devices?
Targeted Questions by Suspected Cause
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Myasthenia Gravis | Fatigable weakness, ptosis, diplopia, bulbar symptoms, worse later in day | “Does your weakness get worse as the day goes on or with repeated activity, and improve after rest?” |
| Guillain-Barré Syndrome | Ascending weakness, areflexia, recent infection, paresthesias | “Did you have a respiratory or gastrointestinal infection in the past 1 to 4 weeks before the weakness started?” |
| Inflammatory Myopathy (Polymyositis, Dermatomyositis) | Proximal weakness, difficulty climbing stairs or rising from chairs, skin rash | “Do you have difficulty getting up from a low chair without using your arms, or trouble climbing stairs or lifting things overhead?” |
| Motor Neuron Disease (Amyotrophic Lateral Sclerosis) | Progressive weakness, fasciculations, mixed upper and lower motor neuron signs, no sensory loss | “Have you noticed muscle twitching under your skin, or has your speech or swallowing changed?” |
| Peripheral Neuropathy | Distal weakness, sensory symptoms (numbness, burning, tingling), foot drop | “Do you have numbness or tingling in your hands or feet along with the weakness? Do you trip or drag your feet?” |
| Spinal Cord Compression | Weakness below a level, sensory level, bowel or bladder dysfunction, back pain | “Do you have back pain? Have you noticed any changes in your bladder or bowel control, or numbness below a certain level on your body?” |
| Stroke | Sudden onset, unilateral weakness, facial droop, speech difficulty | “Did the weakness come on suddenly? Can you tell me exactly what you were doing when it started?” |
| Lambert-Eaton Myasthenic Syndrome | Proximal weakness that improves with activity, dry mouth, smoking history | “Does your strength seem to get better after you’ve been using the muscle for a while? Do you have a very dry mouth or difficulty with erections?” |
| Periodic Paralysis | Episodic weakness, triggered by rest after exercise, carbohydrates, or potassium changes | “Do you have episodes of weakness that come and go, especially after heavy exercise or eating a large meal?” |
| Statin Myopathy | Proximal weakness and myalgias after starting statin, elevated creatine kinase | “When did you start taking a cholesterol medication? Did the weakness or muscle pain begin after starting it?” |
| Hypothyroid Myopathy | Proximal weakness, fatigue, cold intolerance, weight gain, constipation | “Have you had any changes in your weight, energy level, or tolerance to cold temperatures?” |
| Inclusion Body Myositis | Older patient, asymmetric weakness, finger flexors and quadriceps affected, dysphagia | “Do you have trouble gripping things or opening jars? Is one side weaker than the other?” |
Medication and Exposure History
Medications That Cause Muscle Weakness
- Statins (HMG-CoA reductase inhibitors) — Myalgia, myopathy, rarely rhabdomyolysis; risk increased with higher doses, drug interactions (fibrates, azole antifungals)
- Corticosteroids — Steroid myopathy with chronic use; proximal weakness, especially hip flexors; dose and duration dependent
- Colchicine — Neuromyopathy, especially with renal impairment; affects both nerves and muscles
- Chloroquine and Hydroxychloroquine — Vacuolar myopathy with prolonged use; may also cause neuropathy
- Zidovudine (AZT) — Mitochondrial myopathy with prolonged use
- Amiodarone — Can cause both myopathy and neuropathy
- Immune checkpoint inhibitors — Immune-mediated myositis, myasthenia gravis, or overlap syndromes
- D-Penicillamine — Can induce myasthenia gravis or polymyositis
- Neuromuscular blocking agents — Prolonged weakness in ICU patients (critical illness myopathy)
Social, Occupational, and Family History
- Alcohol: Chronic alcoholic myopathy (proximal weakness); acute alcoholic myopathy with rhabdomyolysis after binge drinking
- Illicit drugs: Cocaine, heroin, amphetamines can cause rhabdomyolysis
- Occupation: Lead exposure (wrist drop), organophosphate exposure (cholinergic crisis)
- Recent travel: Poliomyelitis (unvaccinated, endemic areas), tick paralysis, botulism
- Diet: Licorice ingestion (hypokalemia), undercooked meat (trichinosis)
- Family history: Muscular dystrophies, hereditary neuropathies (Charcot-Marie-Tooth), periodic paralysis, myotonic dystrophy — ask about relatives who use wheelchairs, have gait problems, or died young
- Recent infection: Guillain-Barré syndrome (Campylobacter, CMV, EBV, Zika), viral myositis (influenza, COVID-19), post-polio syndrome
Functional Assessment Questions
| Function | Question to Ask | What It Tests |
|---|---|---|
| Rising from chair | “Can you get up from a chair without using your arms?” | Hip flexor and quadriceps strength (proximal lower extremity) |
| Climbing stairs | “Can you climb stairs without using the handrail? How many flights?” | Hip and knee extensors, overall lower extremity strength |
| Overhead activities | “Can you reach into high cupboards or comb your hair without difficulty?” | Shoulder abductors and flexors (proximal upper extremity) |
| Fine motor tasks | “Do you have trouble buttoning shirts, turning keys, or opening jars?” | Hand intrinsic muscles, grip strength (distal upper extremity) |
| Walking and balance | “Do you trip or fall? Do you need to hold onto furniture or walls?” | Ankle dorsiflexors (foot drop), overall gait stability |
| Respiratory function | “Do you get short of breath lying flat? Is your voice weaker at the end of sentences?” | Diaphragm and accessory respiratory muscles |
| Swallowing | “Do you choke on food or liquids? Does food get stuck?” | Bulbar muscles (pharyngeal weakness) |
4. Physical Examination
A systematic approach for evaluating muscle weakness
Systematic Framework: The neurological examination for weakness follows a structured approach: Inspection → Tone → Power → Reflexes → Sensation → Coordination → Gait. The goal is to localize the lesion along the motor pathway (upper motor neuron, lower motor neuron, neuromuscular junction, or muscle) before generating a differential diagnosis.
General Inspection
- Body habitus: Cushingoid appearance (steroid myopathy), cachexia (malignancy, motor neuron disease), obesity (obstructive sleep apnea contributing to fatigue)
- Posture: Hyperlordosis (proximal weakness compensation), scoliosis (longstanding neuromuscular disease), head drop (neck extensor weakness)
- Respiratory pattern: Use of accessory muscles, paradoxical abdominal breathing (diaphragmatic weakness), tachypnea
- Skin: Heliotrope rash around eyes, Gottron papules over knuckles (dermatomyositis), café-au-lait spots (neurofibromatosis), erythema nodosum (sarcoidosis)
- Muscle bulk: Atrophy (denervation or disuse), pseudohypertrophy (Duchenne muscular dystrophy — enlarged calves with fatty replacement)
- Fasciculations: Visible twitching under the skin (lower motor neuron disease, especially amyotrophic lateral sclerosis)
- Ptosis: Unilateral or bilateral drooping eyelids (myasthenia gravis, Horner syndrome, third nerve palsy)
Vital Signs
| Vital Sign | What to Look For | Clinical Significance |
|---|---|---|
| Respiratory Rate and Pattern | Tachypnea, use of accessory muscles, inability to speak in full sentences, paradoxical breathing | Respiratory muscle weakness; impending respiratory failure in Guillain-Barré syndrome or myasthenic crisis |
| Oxygen Saturation | Hypoxemia, especially when supine | Diaphragmatic weakness; may be normal until late in respiratory failure |
| Heart Rate | Tachycardia, bradycardia, arrhythmia | Autonomic dysfunction (Guillain-Barré syndrome), thyroid disease, electrolyte abnormalities |
| Blood Pressure | Hypertension, hypotension, orthostatic changes, labile blood pressure | Autonomic instability (Guillain-Barré syndrome), hypertensive emergency with stroke |
| Temperature | Fever | Infectious etiology (viral myositis, epidural abscess), inflammatory myopathy, neuroleptic malignant syndrome |
Bedside Respiratory Assessment
Critical Assessment — Do Not Skip
Respiratory failure is the leading cause of death in acute neuromuscular weakness. Perform these bedside tests in all patients with acute weakness:
- Single breath count: Ask patient to take a deep breath and count as high as possible — normal is greater than 20; less than 10 suggests severe weakness
- Forced vital capacity (FVC): Less than 20 mL/kg or declining suggests need for ICU monitoring (the “20/30/40 rule” — FVC less than 20, MIP less than 30, MEP less than 40)
- Negative inspiratory force (NIF/MIP): Less than -30 cm H₂O indicates significant diaphragmatic weakness
- Paradoxical breathing: Abdomen moves inward during inspiration (diaphragm paralysis)
- Orthopnea: Ask about breathing difficulty when lying flat
Cranial Nerve Examination
| Cranial Nerve | Test | Abnormal Finding | Suggests |
|---|---|---|---|
| II, III (Pupils) | Pupillary light reflex | Dilated, poorly reactive pupils | Botulism, Miller Fisher syndrome |
| III, IV, VI (Eye movements) | Extraocular movements, pursuit, saccades | Ophthalmoplegia, diplopia | Myasthenia gravis, Miller Fisher syndrome, botulism, brainstem lesion |
| III (Levator palpebrae) | Observe eyelid position; fatigability test (sustained upgaze for 60 seconds) | Ptosis, worsening with sustained upgaze | Myasthenia gravis (fatigable), Horner syndrome, third nerve palsy |
| V (Trigeminal) | Facial sensation, jaw strength, corneal reflex | Facial numbness, weak jaw closure | Brainstem lesion, trigeminal neuropathy |
| VII (Facial) | Facial symmetry, smile, eye closure, forehead wrinkling | Facial weakness (upper vs lower face pattern) | Upper motor neuron (forehead spared) vs lower motor neuron (entire face affected) |
| IX, X (Bulbar) | Palate elevation (“say ahh”), gag reflex, voice quality | Nasal speech, palate asymmetry, absent gag, pooling of secretions | Bulbar weakness — myasthenia gravis, amyotrophic lateral sclerosis, Guillain-Barré syndrome |
| XI (Accessory) | Shoulder shrug, head turn against resistance | Weak sternocleidomastoid or trapezius | Accessory nerve palsy, motor neuron disease |
| XII (Hypoglossal) | Tongue protrusion, inspection for atrophy and fasciculations | Tongue deviation, atrophy, fasciculations | Lower motor neuron: tongue deviates toward weak side; amyotrophic lateral sclerosis if fasciculations present |
Motor Examination
Inspection for Atrophy and Fasciculations
- Compare muscle bulk bilaterally; look for asymmetry
- Check thenar and hypothenar eminences (hand intrinsics), first dorsal interosseous, quadriceps, gastrocnemius
- Observe for fasciculations at rest — spontaneous, irregular twitching visible under skin (best seen in tongue, deltoid, quadriceps)
- Percussion of muscle may provoke fasciculations in motor neuron disease
Tone Assessment
| Finding | Description | Indicates |
|---|---|---|
| Spasticity | Velocity-dependent increase in tone; “clasp-knife” quality (initial resistance then gives way) | Upper motor neuron lesion (stroke, spinal cord disease, multiple sclerosis) |
| Rigidity | Increased tone throughout range of motion; “lead pipe” or “cogwheel” (with tremor) | Extrapyramidal disease (Parkinson disease, drug-induced parkinsonism) |
| Hypotonia/Flaccidity | Reduced resistance to passive movement; floppy limbs | Lower motor neuron lesion, acute upper motor neuron lesion (spinal shock), cerebellar disease, myopathy |
| Myotonia | Delayed relaxation after muscle contraction; “grip myotonia” — difficulty releasing handshake | Myotonic dystrophy, myotonia congenita |
Strength Testing — Medical Research Council (MRC) Scale
| Grade | Description |
|---|---|
| 5 | Normal power against full resistance |
| 4 | Active movement against gravity and resistance (can subdivide: 4+, 4, 4-) |
| 3 | Active movement against gravity only (no added resistance) |
| 2 | Active movement with gravity eliminated (horizontal plane only) |
| 1 | Flicker or trace of contraction visible or palpable |
| 0 | No contraction |
Key Muscles to Test by Region
Upper Extremity
Proximal:
- Shoulder abduction (C5) — Deltoid
- Elbow flexion (C5-C6) — Biceps
- Elbow extension (C7) — Triceps
Distal:
- Wrist extension (C6-C7) — Extensor carpi radialis
- Finger extension (C7) — Extensor digitorum
- Finger abduction (T1) — First dorsal interosseous
- Thumb abduction (T1) — Abductor pollicis brevis
Lower Extremity
Proximal:
- Hip flexion (L1-L2) — Iliopsoas
- Hip abduction (L4-L5) — Gluteus medius
- Knee extension (L3-L4) — Quadriceps
- Knee flexion (L5-S1) — Hamstrings
Distal:
- Ankle dorsiflexion (L4-L5) — Tibialis anterior
- Great toe extension (L5) — Extensor hallucis longus
- Ankle plantarflexion (S1-S2) — Gastrocnemius
Special Tests and Maneuvers
| Test | How to Perform | Positive Finding | Significance |
|---|---|---|---|
| Gower sign | Ask patient to rise from sitting on floor | Patient “walks up” their own legs using hands on thighs | Proximal (hip girdle) weakness — myopathy, especially muscular dystrophy |
| Fatigability test | Sustained upgaze for 60-90 seconds; repeated grip strength | Progressive ptosis or weakening grip with repetition | Myasthenia gravis — weakness worsens with sustained effort |
| Ice pack test | Apply ice to closed eyelid for 2 minutes | Improvement of ptosis after cooling | Suggestive of myasthenia gravis (cold inhibits acetylcholinesterase) |
| Cogan lid twitch | Ask patient to look down for 15 seconds, then quickly look up | Eyelid overshoots then falls back | Myasthenia gravis |
| Curtain sign (orbicularis oculi) | Ask patient to close eyes tightly while you try to open them | Lashes visible when eyes closed (“peek sign”) or weak eye closure | Myasthenia gravis, facial weakness |
| Pronator drift | Arms extended, palms up, eyes closed for 20-30 seconds | Arm pronates and drifts downward | Upper motor neuron weakness (corticospinal tract lesion) |
| Finger roll test | Ask patient to rotate extended index fingers around each other | One finger moves slowly or erratically | Subtle upper motor neuron weakness |
| Heel-to-shin test | Run heel smoothly down opposite shin from knee to ankle | Irregular, jerky movement or inability to perform | Cerebellar dysfunction or weakness |
Deep Tendon Reflexes
| Reflex | Nerve Root | Grading Scale |
|---|---|---|
| Biceps | C5-C6 |
0 — Absent 1+ — Diminished 2+ — Normal 3+ — Brisk (may be normal) 4+ — Clonus (pathological) |
| Brachioradialis | C5-C6 | |
| Triceps | C7-C8 | |
| Patellar (knee jerk) | L3-L4 | |
| Achilles (ankle jerk) | S1-S2 | |
| Jaw jerk | CN V (trigeminal) |
Pathological Reflexes
- Babinski sign: Stroke lateral sole from heel to toes; positive = great toe extension with fanning of other toes (upper motor neuron lesion)
- Hoffman sign: Flick distal phalanx of middle finger downward; positive = thumb and index finger flexion (upper motor neuron lesion)
- Clonus: Sustained rhythmic contractions with sudden dorsiflexion of ankle or wrist; indicates upper motor neuron lesion
Sensory Examination
Why Test Sensation in a Weakness Workup?
Sensory findings help localize the lesion:
- Pure motor findings (no sensory loss): Motor neuron disease, pure motor neuropathy, neuromuscular junction disorder, myopathy
- Sensory loss in dermatomal pattern: Radiculopathy
- Glove-and-stocking sensory loss: Peripheral polyneuropathy
- Sensory level on trunk: Spinal cord lesion
- Hemisensory loss: Contralateral brain or brainstem lesion
Gait Examination
| Gait Pattern | Description | Suggests |
|---|---|---|
| Waddling gait | Side-to-side trunk sway, exaggerated lumbar lordosis | Proximal (hip girdle) weakness — myopathy |
| Steppage gait | High knee lift to clear foot due to foot drop; slapping of foot on ground | Ankle dorsiflexor weakness — peroneal neuropathy, L5 radiculopathy, peripheral neuropathy |
| Spastic gait | Stiff, circumducting leg; scissoring in severe cases | Upper motor neuron lesion — stroke, spinal cord disease |
| Ataxic gait | Wide-based, unsteady, irregular steps | Cerebellar dysfunction or sensory ataxia (proprioceptive loss) |
| Trendelenburg gait | Pelvis drops on the unsupported side during single-leg stance | Hip abductor weakness (gluteus medius) |
Expected Findings by Etiology
| Condition | Distribution | Tone | Reflexes | Atrophy | Sensory | Other Findings |
|---|---|---|---|---|---|---|
| Stroke | Hemiparesis (face, arm, leg) | ↑ Spasticity (delayed) | ↑ Hyperreflexia | Minimal (late) | Hemisensory loss possible | Babinski positive, facial weakness (UMN pattern) |
| Guillain-Barré Syndrome | Ascending, symmetric | ↓ Flaccid | ↓ Areflexia | Minimal (acute) | Paresthesias, mild sensory loss | Autonomic instability, respiratory weakness |
| Motor Neuron Disease (ALS) | Asymmetric, spreads | Mixed: ↑ and ↓ | Mixed: ↑ and ↓ | Prominent | Absent | Fasciculations, bulbar signs, UMN + LMN signs together |
| Myasthenia Gravis | Ocular, bulbar, proximal | Normal | Normal | Absent | Absent | Fatigable weakness, ptosis, diplopia |
| Inflammatory Myopathy | Proximal, symmetric | Normal to ↓ | Normal to ↓ | Variable | Absent | Skin rash (dermatomyositis), dysphagia |
| Peripheral Polyneuropathy | Distal, symmetric | ↓ | ↓ (distal first) | Distal atrophy | Glove-and-stocking | Foot drop, steppage gait |
| Spinal Cord Compression | Below lesion level | ↑ Below level | ↑ Below level | Minimal | Sensory level | Bowel and bladder dysfunction, Babinski positive |
Important Teaching Point
The pattern of weakness matters more than the severity. A detailed motor examination that accurately localizes the weakness to upper motor neuron, lower motor neuron, neuromuscular junction, or muscle will dramatically narrow the differential diagnosis. Pay close attention to:
- Proximal versus distal distribution
- Symmetric versus asymmetric involvement
- Presence or absence of sensory findings
- Reflex pattern (increased versus decreased)
- Presence of fasciculations or atrophy
These five features together will localize most cases of weakness before any investigations are ordered.
5. Differential Diagnosis
Systematic approach organized by probability, duration, and anatomical localization
Acute Muscle Weakness (Hours to Days)
| Probability | Condition | Key Features | Red Flags |
|---|---|---|---|
| COMMON | Stroke (ischemic or hemorrhagic) | Sudden onset hemiparesis, facial droop, speech difficulty, vascular risk factors | Sudden onset, headache, altered consciousness, time-critical for thrombolysis |
| COMMON | Guillain-Barré Syndrome | Ascending symmetric weakness over days, areflexia, preceding infection 1-4 weeks prior, paresthesias | Rapid progression, respiratory involvement, autonomic instability |
| COMMON | Acute radiculopathy (disc herniation) | Dermatomal weakness with radicular pain, sensory loss, reduced reflex in affected root | Cauda equina syndrome: bilateral leg weakness, saddle anesthesia, urinary retention |
| LESS COMMON | Myasthenic crisis | Severe generalized weakness in known myasthenia gravis, often triggered by infection or medication | Respiratory failure, inability to clear secretions, requires ICU |
| LESS COMMON | Acute transverse myelitis | Bilateral weakness with sensory level, bowel and bladder dysfunction, back pain | Rapid progression, may indicate spinal cord compression requiring emergent imaging |
| LESS COMMON | Hypokalemic or hyperkalemic periodic paralysis | Episodic weakness, often after heavy exercise, large carbohydrate meal, or potassium shifts | Cardiac arrhythmias with severe potassium abnormalities |
| LESS COMMON | Rhabdomyolysis | Muscle pain, weakness, dark urine, elevated creatine kinase (often greater than 10,000 U/L) | Acute kidney injury, hyperkalemia, compartment syndrome |
| UNCOMMON BUT SERIOUS | Spinal cord compression (epidural abscess, metastasis, hematoma) | Back pain, weakness below level, sensory level, sphincter dysfunction | Surgical emergency — irreversible paralysis if not decompressed within hours |
| UNCOMMON BUT SERIOUS | Botulism | Descending paralysis starting with cranial nerves (diplopia, dysphagia), dilated pupils, autonomic symptoms | Respiratory failure, food-borne or wound source |
| UNCOMMON BUT SERIOUS | Tick paralysis | Ascending flaccid paralysis, areflexia, recent outdoor exposure, attached tick often found on scalp | Respiratory failure; rapid recovery after tick removal |
Subacute Muscle Weakness (Weeks to Months)
Step-by-Step Approach to Subacute Weakness:
- Step 1: Rule out medication-induced causes — Review all medications, especially statins, corticosteroids, and immune checkpoint inhibitors
- Step 2: Consider inflammatory and autoimmune etiologies — Often treatable if identified early
- Step 3: Evaluate for malignancy — Paraneoplastic syndromes and direct tumor involvement
- Step 4: Check metabolic and endocrine causes — Thyroid function, electrolytes, vitamin levels
| Probability | Condition | Approximate Frequency | Key Distinguishing Features |
|---|---|---|---|
| COMMON | Inflammatory myopathies (dermatomyositis, polymyositis, immune-mediated necrotizing myopathy) | Most common cause of subacute proximal weakness in adults | Symmetric proximal weakness, elevated creatine kinase, skin rash in dermatomyositis (heliotrope, Gottron papules) |
| COMMON | Drug-induced myopathy (statins, corticosteroids) | Up to 10% of statin users report myalgias; true myopathy less common | Temporal relationship to medication initiation or dose increase; often improves with discontinuation |
| COMMON | Chronic inflammatory demyelinating polyneuropathy (CIDP) | Most common treatable chronic neuropathy | Progressive symmetric proximal and distal weakness, areflexia, sensory involvement, nerve conduction slowing |
| LESS COMMON | Thyroid myopathy (hypothyroid or hyperthyroid) | Myopathy present in up to 80% of hypothyroid patients | Hypothyroid: proximal weakness, delayed relaxation of reflexes, elevated CK. Hyperthyroid: proximal weakness with normal or low CK |
| LESS COMMON | Subacute combined degeneration (vitamin B12 deficiency) | Increasingly recognized, especially in elderly and post-bariatric surgery | Weakness with prominent sensory ataxia, paresthesias, cognitive changes, macrocytic anemia |
| LESS COMMON | Lambert-Eaton myasthenic syndrome | 60% associated with small cell lung cancer | Proximal weakness that improves with activity (facilitation), dry mouth, hyporeflexia improving after exercise |
| UNCOMMON BUT SERIOUS | Paraneoplastic syndromes | May precede cancer diagnosis by months to years | Subacute onset, may have associated antibodies (anti-Hu, anti-Yo), search for occult malignancy |
| UNCOMMON BUT SERIOUS | HIV-associated myopathy or neuropathy | Common in untreated HIV; also antiretroviral-related | Risk factors for HIV, may have other HIV manifestations |
Chronic Muscle Weakness (Greater than 6 Months)
| Probability | Condition | Approximate Frequency | Key Distinguishing Features |
|---|---|---|---|
| COMMON | Diabetic polyneuropathy | Affects 50% of diabetic patients over time | Length-dependent, distal greater than proximal, sensory symptoms prominent, foot drop in severe cases |
| COMMON | Myasthenia gravis | Prevalence approximately 20 per 100,000 | Fatigable weakness, ocular symptoms (ptosis, diplopia), bulbar weakness, diurnal variation (worse later in day) |
| COMMON | Chronic radiculopathy or spinal stenosis | Very common in elderly population | Dermatomal weakness, neurogenic claudication (stenosis), back or neck pain |
| LESS COMMON | Amyotrophic lateral sclerosis (ALS) | Incidence 2-3 per 100,000 per year | Progressive weakness with mixed upper and lower motor neuron signs, fasciculations, no sensory loss, bulbar involvement |
| LESS COMMON | Inclusion body myositis | Most common acquired myopathy in patients over 50 | Asymmetric weakness, finger flexors and quadriceps preferentially affected, dysphagia, poor response to immunotherapy |
| LESS COMMON | Hereditary neuropathies (Charcot-Marie-Tooth disease) | Most common inherited neuromuscular disorder | Distal weakness, high arches (pes cavus), hammer toes, family history, slowly progressive since childhood |
| LESS COMMON | Muscular dystrophies (limb-girdle, facioscapulohumeral) | Variable; FSHD affects 1 in 8,000-20,000 | Proximal weakness, characteristic patterns (scapular winging in FSHD), family history, slowly progressive |
| UNCOMMON BUT SERIOUS | Myotonic dystrophy | Most common adult muscular dystrophy (1 in 8,000) | Myotonia (grip myotonia, percussion myotonia), distal weakness, cataracts, cardiac conduction abnormalities, characteristic facies |
| UNCOMMON BUT SERIOUS | Metabolic myopathies (Pompe disease, McArdle disease) | Rare but treatable (enzyme replacement for Pompe) | Exercise intolerance, second-wind phenomenon (McArdle), respiratory involvement (late-onset Pompe) |
Anatomical Localization Approach
Upper Motor Neuron (Brain and Spinal Cord)
Stroke
Multiple sclerosis
Spinal cord compression
Transverse myelitis
Amyotrophic lateral sclerosis (UMN component)
Primary lateral sclerosis
Hereditary spastic paraplegia
Lower Motor Neuron (Anterior Horn and Nerve)
Amyotrophic lateral sclerosis (LMN component)
Spinal muscular atrophy
Poliomyelitis and post-polio syndrome
Radiculopathy
Plexopathy
Peripheral polyneuropathy
Mononeuropathy (carpal tunnel, peroneal)
Guillain-Barré syndrome
CIDP
Neuromuscular Junction
Myasthenia gravis
Lambert-Eaton myasthenic syndrome
Botulism
Organophosphate poisoning
Drug-induced (aminoglycosides, magnesium)
Congenital myasthenic syndromes
Muscle (Myopathy)
Inflammatory myopathies
Muscular dystrophies
Toxic and drug-induced myopathies
Endocrine myopathies
Metabolic myopathies
Infectious myositis
Critical illness myopathy
Inclusion body myositis
Drug-Induced Muscle Weakness
| Drug or Drug Class | Mechanism | Characteristics | Time to Resolution After Stopping |
|---|---|---|---|
| Statins (HMG-CoA reductase inhibitors) | Mitochondrial dysfunction, CoQ10 depletion, immune-mediated (anti-HMGCR antibodies) | Myalgias common; true myopathy with elevated CK less common; immune-mediated form may not resolve | Weeks to months for toxic myopathy; immune-mediated may persist |
| Corticosteroids | Increased protein catabolism, decreased protein synthesis, type II fiber atrophy | Proximal weakness (especially hip flexors), normal CK, dose and duration dependent | Months (may take 3-6 months for full recovery) |
| Colchicine | Disruption of microtubule function affecting both nerve and muscle | Neuromyopathy with proximal weakness and neuropathy; elevated CK; risk increases with renal impairment | Weeks to months |
| Chloroquine and Hydroxychloroquine | Lysosomal dysfunction causing vacuolar myopathy | Slowly progressive proximal weakness; may also cause neuropathy and cardiomyopathy | Months to years; may be irreversible |
| Zidovudine (AZT) | Mitochondrial toxicity (inhibits mitochondrial DNA polymerase gamma) | Proximal myopathy, elevated CK, ragged red fibers on biopsy | Weeks to months |
| Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab) | Immune-mediated inflammation; may cause myositis, myasthenia gravis, or overlap | Can be severe; may have concurrent myocarditis; check troponin | Variable; may require immunosuppression |
| Fibrates (gemfibrozil, fenofibrate) | Similar to statins; risk markedly increased when combined with statins | Myopathy and rhabdomyolysis, especially with statin combination | Weeks |
| Amiodarone | Lysosomal dysfunction; may also cause neuropathy | Proximal myopathy; long half-life prolongs toxicity | Months (very long half-life) |
| D-Penicillamine | Immune-mediated; can induce myasthenia gravis or polymyositis | May develop autoantibodies; clinical syndrome identical to idiopathic forms | Months; may persist after discontinuation |
| Alcohol | Direct toxicity, nutritional deficiency, electrolyte disturbances | Acute: rhabdomyolysis after binge. Chronic: progressive proximal myopathy | Months with abstinence; may not fully recover |
Quick Reference: “If You See This, Think This”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| Sudden hemiparesis with facial droop | Stroke | Emergent CT head, activate stroke protocol |
| Ascending weakness with areflexia after viral illness | Guillain-Barré syndrome | Lumbar puncture (albuminocytologic dissociation), nerve conduction studies, monitor respiratory function |
| Fatigable ptosis and diplopia worse in evening | Myasthenia gravis | Acetylcholine receptor antibodies, ice pack test, repetitive nerve stimulation |
| Proximal weakness with heliotrope rash | Dermatomyositis | CK, myositis-specific antibodies, EMG, muscle biopsy, malignancy screening |
| Mixed UMN and LMN signs with fasciculations, no sensory loss | Amyotrophic lateral sclerosis | EMG (widespread denervation), MRI to exclude structural lesions |
| Weakness below a level with sensory level and bladder dysfunction | Spinal cord compression | Emergent MRI spine, neurosurgical consultation |
| Proximal weakness in patient on statin | Statin myopathy | Check CK, stop statin, reassess in 4-6 weeks; if persistent, check anti-HMGCR antibodies |
| Distal weakness with sensory loss in glove-and-stocking pattern | Peripheral polyneuropathy | Glucose, HbA1c, B12, TSH, SPEP, nerve conduction studies |
| Descending paralysis with dilated pupils after eating canned food | Botulism | Stool and serum for botulinum toxin, EMG, antitoxin administration |
| Episodic weakness after large carbohydrate meal | Hypokalemic periodic paralysis | Check potassium during attack, genetic testing, trial of potassium |
| Older patient with asymmetric weakness affecting finger flexors and quadriceps | Inclusion body myositis | CK (often only mildly elevated), EMG, muscle biopsy (rimmed vacuoles) |
| Proximal weakness improving with repeated effort, dry mouth, smoking history | Lambert-Eaton myasthenic syndrome | Voltage-gated calcium channel antibodies, EMG with repetitive stimulation, CT chest for malignancy |
6. Diagnostic Investigations
A stepwise, cost-effective approach guided by clinical localization
Baseline Investigations for All Patients with Unexplained Weakness
| Investigation | Purpose | What to Look For | Practical Points |
|---|---|---|---|
| Complete blood count | Screen for anemia, infection, hematologic malignancy | Macrocytic anemia (B12 deficiency), lymphopenia (HIV, autoimmune) | May be normal in many neuromuscular diseases |
| Comprehensive metabolic panel | Electrolytes, renal and liver function | Hypokalemia, hyperkalemia, hypercalcemia, hypomagnesemia, renal failure | Potassium critical in periodic paralysis; check during attack if episodic |
| Creatine kinase (CK) | Marker of muscle damage | Elevated: myopathy, rhabdomyolysis, motor neuron disease. Normal: neuropathy, NMJ disorders, steroid myopathy | Can be elevated after vigorous exercise, IM injections, or EMG; repeat if borderline |
| Thyroid function tests (TSH, free T4) | Screen for thyroid myopathy | Hypothyroidism (weakness, elevated CK, delayed reflexes) or hyperthyroidism (weakness, normal CK) | Thyroid disease is common and treatable cause of weakness |
| Vitamin B12 level | Screen for subacute combined degeneration | Low B12 with weakness, sensory ataxia, and cognitive changes | Check methylmalonic acid if B12 borderline low (200-400 pg/mL) |
| Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) | Screen for inflammatory conditions | Elevated in inflammatory myopathies, vasculitis, infections | May be normal in some inflammatory myopathies |
| Hemoglobin A1c or fasting glucose | Screen for diabetes (common cause of neuropathy) | Diabetes or prediabetes | Diabetic neuropathy can occur even with prediabetes |
Targeted Investigations by Suspected Localization
If Suspecting Upper Motor Neuron Lesion (Brain or Spinal Cord)
First-Line Tests
- CT head (non-contrast): Immediate if acute stroke suspected; identifies hemorrhage within minutes
- MRI brain with and without contrast: Gold standard for stroke (diffusion-weighted imaging), demyelination, tumor, infection
- MRI spine with and without contrast: Essential for myelopathy; identifies compression, transverse myelitis, demyelination
Second-Line Tests
- Lumbar puncture: If infection, inflammation, or demyelination suspected; CSF analysis for cells, protein, oligoclonal bands
- MR angiography or CT angiography: If vascular lesion suspected
- Visual evoked potentials: Evidence of demyelination (multiple sclerosis)
- Aquaporin-4 (NMO-IgG) and MOG antibodies: If neuromyelitis optica spectrum disorder suspected
If Suspecting Lower Motor Neuron Lesion (Anterior Horn Cell, Nerve Root, Peripheral Nerve)
First-Line Tests
- Electromyography (EMG) and nerve conduction studies (NCS): Distinguishes neuropathy from myopathy; identifies denervation, demyelination, conduction block
- MRI spine: For radiculopathy — identifies disc herniation, foraminal stenosis, tumor
- Lumbar puncture: For Guillain-Barré syndrome (albuminocytologic dissociation: elevated protein, normal cells)
Second-Line Tests
- Serum protein electrophoresis (SPEP) and immunofixation: Screen for paraproteinemia associated with neuropathy
- Anti-ganglioside antibodies (GM1, GD1a, GQ1b): Guillain-Barré syndrome variants, multifocal motor neuropathy
- Genetic testing: Hereditary neuropathies (Charcot-Marie-Tooth — PMP22 duplication most common)
- Nerve biopsy: Rarely needed; consider for vasculitic neuropathy, amyloidosis
If Suspecting Neuromuscular Junction Disorder
For Myasthenia Gravis
- Acetylcholine receptor (AChR) antibodies: Positive in 85% of generalized MG, 50% of ocular MG
- Muscle-specific kinase (MuSK) antibodies: Positive in 40% of AChR-negative MG
- LRP4 antibodies: Consider if AChR and MuSK negative
- Repetitive nerve stimulation: Decremental response (greater than 10% decrement) supports diagnosis
- Single-fiber EMG: Most sensitive test; increased jitter
- CT chest: Screen for thymoma (present in 10-15% of MG patients)
For Lambert-Eaton Myasthenic Syndrome
- Voltage-gated calcium channel (VGCC) antibodies: Positive in greater than 90%
- Repetitive nerve stimulation: Incremental response (greater than 100% increment at high-frequency stimulation)
- CT chest, abdomen, pelvis: Search for small cell lung cancer (present in 50-60%)
- PET-CT: If CT negative but high clinical suspicion for malignancy
If Suspecting Myopathy
First-Line Tests
- Creatine kinase: Often markedly elevated (5-50 times normal) in inflammatory and dystrophic myopathies; may be normal in steroid myopathy
- Aldolase: May be elevated even when CK is normal (especially in dermatomyositis)
- EMG: Myopathic pattern (small, polyphasic motor units with early recruitment); helps distinguish from neuropathy
- MRI of affected muscles: Shows edema in active inflammation; helps guide biopsy site
Second-Line Tests
- Myositis-specific antibodies panel: Anti-Jo-1 (antisynthetase syndrome), anti-Mi-2 (dermatomyositis), anti-SRP, anti-HMGCR (immune-mediated necrotizing myopathy), anti-MDA5
- Muscle biopsy: Gold standard for diagnosis; shows inflammation, necrosis, dystrophic changes, specific patterns
- Genetic testing: For suspected muscular dystrophies (dystrophin gene for Duchenne/Becker, others based on phenotype)
- Malignancy screening: CT chest, abdomen, pelvis; consider PET-CT (dermatomyositis has strong cancer association)
Understanding EMG and Nerve Conduction Studies
| Finding | Neuropathy | Myopathy | Neuromuscular Junction | Motor Neuron Disease |
|---|---|---|---|---|
| Motor nerve conduction velocity | Slowed (demyelinating) or normal (axonal) | Normal | Normal | Normal or mildly reduced |
| Compound muscle action potential (CMAP) amplitude | Reduced (axonal) or normal (demyelinating) | Normal or reduced | Reduced | Reduced |
| Sensory nerve action potential (SNAP) | Abnormal | Normal | Normal | Normal |
| Spontaneous activity (fibrillations, positive sharp waves) | Present in axonal | Present in inflammatory myopathies | Absent | Present (widespread) |
| Motor unit potentials | Large, polyphasic (chronic reinnervation) | Small, polyphasic, early recruitment | Normal morphology, varying amplitude | Large, polyphasic with reduced recruitment |
| Repetitive nerve stimulation | Normal | Normal | Decrement (MG) or increment (LEMS) | Normal |
Special Investigations
Lumbar Puncture — When to Perform
| Indication | Expected CSF Finding | Clinical Significance |
|---|---|---|
| Guillain-Barré syndrome | Elevated protein (greater than 45 mg/dL), normal cell count (albuminocytologic dissociation) | Supports diagnosis; may be normal in first week |
| CIDP | Elevated protein, normal cells | Similar to GBS but chronic course |
| Multiple sclerosis | Oligoclonal bands (present in CSF, absent in serum), elevated IgG index | Supports demyelinating disease |
| CNS infection | Pleocytosis, elevated protein, glucose depends on organism | Bacterial (neutrophils, low glucose), viral (lymphocytes, normal glucose) |
| Carcinomatous meningitis | Malignant cells on cytology, elevated protein | May require multiple LPs; consider MRI spine with contrast |
Muscle Biopsy — Indications and Findings
| Condition | Characteristic Biopsy Findings |
|---|---|
| Polymyositis | Endomysial inflammation with CD8+ T-cells, muscle fiber necrosis and regeneration |
| Dermatomyositis | Perifascicular atrophy, perivascular inflammation, complement deposition on capillaries |
| Inclusion body myositis | Rimmed vacuoles, endomysial inflammation, congophilic inclusions |
| Immune-mediated necrotizing myopathy | Prominent necrosis with minimal inflammation, macrophage infiltration |
| Muscular dystrophy | Variation in fiber size, fibrosis, fatty replacement; immunohistochemistry for specific proteins (dystrophin) |
| Mitochondrial myopathy | Ragged red fibers (modified Gomori trichrome), cytochrome oxidase-negative fibers |
Empiric Treatment Trials as Diagnostic Tools
In some situations, response to treatment supports the diagnosis:
- Pyridostigmine trial: Improvement supports myasthenia gravis (use with caution; edrophonium test rarely used now due to cardiac risks)
- Thyroid hormone replacement: Improvement in weakness supports hypothyroid myopathy
- Statin discontinuation: Resolution of weakness within weeks supports statin myopathy (immune-mediated form will not improve)
- Corticosteroid trial: Improvement supports inflammatory myopathy (except inclusion body myositis, which typically does not respond)
- Intravenous immunoglobulin (IVIG): Improvement supports CIDP, multifocal motor neuropathy, or certain inflammatory conditions
Stepwise Investigation Algorithm
Approach Based on Clinical Localization:
- All patients: CBC, CMP (including potassium, calcium, magnesium), CK, TSH, B12, glucose/HbA1c, ESR/CRP
- If upper motor neuron pattern: MRI brain and/or spine (depending on localization)
- If lower motor neuron pattern: EMG/NCS first; MRI spine if radiculopathy suspected
- If neuromuscular junction suspected: Antibody testing (AChR, MuSK, VGCC), repetitive nerve stimulation, CT chest
- If myopathy suspected: CK, EMG, myositis-specific antibodies, MRI muscle; proceed to muscle biopsy if diagnosis unclear
- If no diagnosis after initial workup: Consider lumbar puncture, genetic testing, or referral to neuromuscular specialist
7. Pattern Recognition and Clinical Decision-Making
Practical algorithms and decision pathways
Step 1: Is This Urgent?
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Respiratory muscle weakness — dyspnea at rest, paradoxical breathing, unable to count to 10, FVC less than 20 mL/kg | EMERGENT | ICU admission, prepare for intubation, serial FVC monitoring every 2-4 hours |
| Acute hemiparesis with facial droop — sudden onset, within thrombolysis window | EMERGENT | Activate stroke code, emergent CT head, consider thrombolysis or thrombectomy |
| Spinal cord compression — weakness below a level, sensory level, bladder dysfunction, back pain | EMERGENT | Emergent MRI spine, IV dexamethasone if malignancy suspected, neurosurgical consultation |
| Rapidly ascending weakness — weakness progressing over hours to days, areflexia | EMERGENT | Admit to ICU or monitored setting, serial FVC, lumbar puncture, prepare for IVIG or plasmapheresis |
| Bulbar weakness with aspiration risk — severe dysphagia, pooling secretions, weak cough | URGENT | NPO status, speech therapy evaluation, consider NG tube, assess for myasthenic crisis |
| Rhabdomyolysis — dark urine, muscle pain, CK greater than 10,000 U/L | URGENT | Aggressive IV fluid resuscitation, monitor renal function and potassium, identify cause |
| New weakness in patient on immune checkpoint inhibitor | URGENT | Check CK, troponin (myocarditis risk), hold checkpoint inhibitor, consider steroids |
| Subacute progressive proximal weakness — over weeks, elevated CK | ROUTINE | Outpatient workup with EMG, myositis antibodies, consider muscle biopsy |
| Chronic slowly progressive weakness — months to years, stable | ROUTINE | Outpatient neurology referral, EMG/NCS, targeted testing based on pattern |
Step 2: Localize the Lesion
The Most Critical Step: Before ordering tests or generating a differential, determine WHERE the problem is:
| Clinical Features | Localization | Proceed To |
|---|---|---|
| Hyperreflexia, spasticity, Babinski positive, no atrophy, weakness in pyramidal pattern | Upper Motor Neuron | Algorithm A — Brain and Spinal Cord |
| Hyporeflexia or areflexia, flaccidity, atrophy, fasciculations, dermatomal or nerve distribution | Lower Motor Neuron | Algorithm B — Anterior Horn Cell and Peripheral Nerve |
| Fatigable weakness, normal reflexes, no sensory loss, ptosis and diplopia | Neuromuscular Junction | Algorithm C — NMJ Disorders |
| Proximal greater than distal weakness, normal or reduced reflexes, no sensory loss, elevated CK | Muscle | Algorithm D — Myopathy |
| Mixed UMN and LMN signs, fasciculations, no sensory loss, progressive | Motor Neuron Disease | Algorithm E — ALS Evaluation |
Step 3: Follow the Appropriate Algorithm
Algorithm A: Upper Motor Neuron Weakness
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Sudden onset hemiparesis, within 24 hours | Stroke (ischemic or hemorrhagic) | Emergent CT head → if ischemic and within window, thrombolysis/thrombectomy evaluation |
| Weakness below a level with sensory level, back pain | Spinal cord compression or myelopathy | Emergent MRI spine → neurosurgical consultation if compression |
| Relapsing-remitting symptoms, young patient, multiple lesions | Multiple sclerosis | MRI brain and spine with contrast → lumbar puncture for oligoclonal bands |
| Progressive spastic paraparesis, family history | Hereditary spastic paraplegia | MRI spine (to exclude structural cause) → genetic testing |
Algorithm B: Lower Motor Neuron Weakness
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Ascending weakness over days, areflexia, recent infection | Guillain-Barré syndrome | ICU admission → LP (elevated protein) → EMG/NCS → IVIG or plasmapheresis |
| Dermatomal weakness with radicular pain | Radiculopathy | MRI of relevant spine level → conservative management or surgical referral |
| Distal symmetric weakness with sensory loss (glove-and-stocking) | Peripheral polyneuropathy | EMG/NCS → glucose, B12, TSH, SPEP → treat underlying cause |
| Progressive proximal and distal weakness over months, areflexia | CIDP | EMG/NCS (demyelinating pattern) → LP → trial of IVIG or steroids |
| Asymmetric weakness, multifocal, pure motor | Multifocal motor neuropathy | EMG (conduction block) → anti-GM1 antibodies → IVIG trial |
Algorithm C: Neuromuscular Junction Disorders
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Fatigable ptosis and diplopia, worse later in day, bulbar symptoms | Myasthenia gravis | AChR antibodies → if negative, MuSK antibodies → CT chest for thymoma → pyridostigmine trial |
| Proximal weakness improving with activity, dry mouth, smoker | Lambert-Eaton myasthenic syndrome | VGCC antibodies → EMG with repetitive stimulation → CT chest for small cell lung cancer |
| Descending paralysis, diplopia, dilated pupils, recent food ingestion or wound | Botulism | Stool and serum botulinum toxin assay → antitoxin → supportive care in ICU |
| Known MG with acute worsening, respiratory distress | Myasthenic crisis | ICU → hold anticholinesterases initially → IVIG or plasmapheresis → identify trigger |
Algorithm D: Myopathy
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Proximal weakness, elevated CK, heliotrope rash or Gottron papules | Dermatomyositis | Myositis antibodies → EMG → MRI → muscle biopsy → malignancy screening |
| Proximal weakness, elevated CK, no rash | Polymyositis or immune-mediated necrotizing myopathy | Myositis antibodies (including anti-HMGCR, anti-SRP) → EMG → muscle biopsy |
| Proximal weakness in patient on statin | Statin myopathy | Stop statin → recheck CK in 4-6 weeks → if persistent, check anti-HMGCR antibodies |
| Proximal weakness in patient on chronic steroids | Steroid myopathy | CK usually normal → EMG may be normal → reduce steroid dose if possible |
| Asymmetric weakness, older patient, finger flexors and quadriceps weak | Inclusion body myositis | CK mildly elevated → EMG → muscle biopsy (rimmed vacuoles) → immunotherapy rarely helps |
| Exercise intolerance, “second wind” phenomenon, myoglobinuria | Metabolic myopathy (McArdle disease) | Forearm exercise test → genetic testing → muscle biopsy if needed |
Algorithm E: Suspected Motor Neuron Disease
| Clinical Scenario | Diagnosis | Action |
|---|---|---|
| Progressive weakness with mixed UMN and LMN signs in multiple regions, fasciculations, no sensory loss | Amyotrophic lateral sclerosis (ALS) | EMG (widespread denervation in 3+ regions) → MRI (exclude structural mimics) → genetic testing if familial → multidisciplinary care |
| Pure LMN syndrome, slowly progressive | Progressive muscular atrophy (LMN-predominant ALS variant) | EMG → exclude other LMN diseases → follow for UMN signs |
| Pure UMN syndrome, slowly progressive | Primary lateral sclerosis | MRI spine → EMG (to exclude LMN involvement) → follow for years before confirming diagnosis |
“What Do I Do If…” Decision Reference
| Clinical Situation | Immediate Action | Next Step |
|---|---|---|
| Patient cannot count to 20 in one breath | Measure FVC immediately; call ICU if FVC less than 20 mL/kg | Serial FVC monitoring every 2-4 hours; prepare for intubation |
| Weakness is rapidly progressing (hours) | Admit to monitored setting; check potassium; assess respiratory function | Lumbar puncture; EMG if available; consider IVIG empirically if GBS suspected |
| Patient has weakness and back pain | Check for sensory level; assess bladder function | Emergent MRI spine if any concern for cord compression |
| Known myasthenia gravis patient becomes weak | Assess respiratory function; differentiate crisis from cholinergic excess | ICU if respiratory compromise; hold pyridostigmine; start IVIG or plasmapheresis |
| CK is greater than 10,000 U/L | Aggressive IV fluids; check renal function and potassium | Monitor urine output; identify and treat underlying cause |
| Patient is on statin and develops weakness | Check CK; stop statin | Reassess in 4-6 weeks; if not improving, check anti-HMGCR antibodies |
| EMG shows widespread denervation with mixed UMN and LMN signs | Consider ALS; obtain MRI to exclude structural mimics | Refer to ALS clinic; discuss diagnosis sensitively; multidisciplinary planning |
| Inflammatory myopathy suspected | Check myositis-specific antibodies; consider malignancy screening | Muscle biopsy for confirmation; initiate immunosuppression with steroids |
| Weakness not improving despite treatment | Reassess diagnosis; consider alternative etiologies | Repeat EMG; consider muscle biopsy; check for overlapping conditions |
Troubleshooting Refractory Weakness
Ask These Questions When Weakness Is Not Improving
- Is the diagnosis correct? — Consider repeating EMG, muscle biopsy, or antibody testing
- Are there multiple overlapping conditions? — For example, statin myopathy plus inflammatory myopathy; myasthenia plus thyroid disease
- Is the treatment adequate? — Dose, duration, and adherence to therapy
- Is there an occult malignancy? — Paraneoplastic syndromes may not respond until cancer is treated
- Is there ongoing exposure? — Continued medication, toxin, or alcohol use
- Has the condition evolved? — Some conditions (like inclusion body myositis) are inherently treatment-resistant
- Is deconditioning contributing? — Physical therapy and rehabilitation may be needed alongside medical treatment
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
Localize before you diagnose: The single most important step in evaluating weakness is determining WHERE the lesion is (upper motor neuron, lower motor neuron, neuromuscular junction, or muscle). This dramatically narrows the differential and guides testing.
Mixed UMN and LMN signs = ALS until proven otherwise: The combination of hyperreflexia and spasticity (UMN) with fasciculations and atrophy (LMN) in the same patient is virtually pathognomonic for amyotrophic lateral sclerosis.
Respiratory failure is the killer in neuromuscular disease: Always assess respiratory function in acute weakness. The “20/30/40 rule” for Guillain-Barré syndrome: FVC less than 20 mL/kg, NIF less than -30 cm H₂O, or MEP less than 40 cm H₂O — consider intubation.
Fatigable weakness = neuromuscular junction: If weakness worsens with repeated activity and improves with rest, think myasthenia gravis. The ice pack test (improvement of ptosis after 2 minutes of ice) is a simple bedside diagnostic tool.
Normal CK does not exclude myopathy: Steroid myopathy, some endocrine myopathies, and late-stage dystrophies may have normal CK levels. Conversely, CK can be mildly elevated after exercise or EMG.
Sensory findings exclude pure motor conditions: Motor neuron disease, myopathy, and neuromuscular junction disorders do NOT cause sensory loss. If sensory symptoms are present, think neuropathy, radiculopathy, or central nervous system lesion.
Check the medication list: Statins are one of the most common causes of myopathy. Always ask about all medications, including over-the-counter supplements and recent changes in dose.
Lambert-Eaton = search for cancer: Up to 60% of Lambert-Eaton myasthenic syndrome cases are associated with small cell lung cancer. CT chest is mandatory, and surveillance may be needed for years.
Critical Pitfalls to Avoid
Missing respiratory compromise: Patients with neuromuscular respiratory weakness may not appear distressed until they are near respiratory failure. Measure FVC and NIF — do not rely on oxygen saturation or appearance alone.
Confusing fatigue with weakness: “Fatigue” is feeling tired; “weakness” is reduced muscle strength on examination. Many patients use these terms interchangeably. Always test actual muscle power.
Dismissing normal examination: Many serious conditions (early myasthenia gravis, early ALS, periodic paralysis between attacks) may have normal or near-normal examination. Trust the history if concerning.
Stopping statin too briefly: Toxic statin myopathy may take weeks to months to resolve. Do not conclude that statin was not the cause after only a few days. However, immune-mediated statin myopathy (anti-HMGCR) will NOT resolve with statin discontinuation alone.
Forgetting to ask about family history: Many neuromuscular diseases are hereditary (muscular dystrophies, hereditary neuropathies, periodic paralysis). Ask specifically about relatives with gait problems, wheelchair use, or early death.
Missing spinal cord compression: Back pain with weakness below a level is a surgical emergency. Delays in diagnosis lead to permanent paralysis. When in doubt, get emergent MRI.
Ordering the wrong test first: EMG before clinical localization wastes time and money. CK before clinical assessment may be misleading. Let the examination guide the investigations.
Assuming negative antibody test excludes myasthenia: Up to 15% of generalized myasthenia and 50% of ocular myasthenia are seronegative. If clinical suspicion is high, proceed with repetitive nerve stimulation and single-fiber EMG.
Key Takeaways
- True weakness (reduced muscle power on examination) must be distinguished from perceived weakness (fatigue, asthenia) — they have entirely different differential diagnoses.
- Anatomical localization is the foundation of neuromuscular diagnosis. Determine if the lesion is in the upper motor neuron, lower motor neuron, neuromuscular junction, or muscle before ordering tests.
- Upper motor neuron signs (hyperreflexia, spasticity, Babinski) indicate brain or spinal cord pathology. Lower motor neuron signs (hyporeflexia, atrophy, fasciculations) indicate anterior horn cell, nerve root, or peripheral nerve pathology.
- Acute ascending weakness with areflexia after a viral infection is Guillain-Barré syndrome until proven otherwise — monitor respiratory function closely and prepare for immunotherapy.
- Respiratory failure is the most dangerous complication of acute neuromuscular weakness. Serial bedside assessments (single breath count, FVC) are more important than oxygen saturation.
- Fatigable weakness (worsening with use, improving with rest) points to the neuromuscular junction — think myasthenia gravis or Lambert-Eaton syndrome.
- Proximal weakness with elevated CK and skin rash is dermatomyositis — always screen for underlying malignancy.
- Drug-induced myopathy is common and treatable. Statins, corticosteroids, and immune checkpoint inhibitors are frequent culprits. Always review the medication list.
- Mixed upper and lower motor neuron signs without sensory loss is the hallmark of amyotrophic lateral sclerosis — a devastating diagnosis requiring sensitive communication and multidisciplinary care.
- When in doubt about spinal cord compression, get an emergent MRI. The window for surgical intervention is narrow, and delays cause irreversible harm.
Quick Reference Algorithm
Systematic Approach to Muscle Weakness:
- Confirm true weakness: Test muscle power on examination — distinguish from fatigue or pain-limited effort
- Assess urgency: Check respiratory function, identify red flags (acute onset, ascending pattern, bulbar symptoms, sensory level)
- Localize the lesion: Upper motor neuron, lower motor neuron, neuromuscular junction, or muscle — based on reflex pattern, tone, atrophy, sensory findings
- Characterize the pattern: Proximal versus distal, symmetric versus asymmetric, acute versus chronic
- Order targeted investigations: Baseline labs (CK, TSH, B12, electrolytes) for all; imaging and EMG based on localization
- Generate differential diagnosis: Based on localization and pattern — prioritize common and treatable causes
- Initiate treatment: Emergent intervention for life-threatening conditions; supportive care while establishing diagnosis
- Arrange follow-up: Neurology referral for complex cases; monitor for progression and treatment response